Shares of Amgen Inc. (NASDAQ:AMGN) have been assigned a consensus recommendation of “Buy” from the twenty-three ratings firms that are covering the company, Marketbeat.com reports. Ten analysts have rated the stock with a hold rating, eleven have given a buy rating and two have issued a strong buy rating on the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $187.81.

A number of brokerages have issued reports on AMGN. Royal Bank Of Canada began coverage on Amgen in a research report on Thursday, September 14th. They set a “sector perform” rating and a $192.00 price target on the stock. BMO Capital Markets reiterated a “hold” rating and set a $199.00 price target on shares of Amgen in a research report on Monday, September 25th. Jefferies Group LLC reiterated a “buy” rating and set a $200.00 price target on shares of Amgen in a research report on Monday, September 25th. Mizuho reiterated a “buy” rating and set a $198.00 price target (up previously from $183.00) on shares of Amgen in a research report on Thursday, September 28th. Finally, Credit Suisse Group reiterated a “neutral” rating and set a $186.00 price target (up previously from $177.00) on shares of Amgen in a research report on Friday, September 29th.

Amgen (NASDAQ AMGN) traded up 0.73% on Wednesday, hitting $188.59. The stock had a trading volume of 1,660,280 shares. Amgen has a 12 month low of $133.64 and a 12 month high of $191.10. The company’s 50 day moving average is $180.38 and its 200-day moving average is $169.99. The stock has a market cap of $137.61 billion, a P/E ratio of 17.18 and a beta of 1.36.

Amgen (NASDAQ:AMGN) last issued its earnings results on Tuesday, July 25th. The medical research company reported $3.27 EPS for the quarter, topping analysts’ consensus estimates of $3.11 by $0.16. The firm had revenue of $5.81 billion for the quarter, compared to the consensus estimate of $5.67 billion. Amgen had a return on equity of 29.85% and a net margin of 35.46%. The company’s revenue was up 2.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.84 earnings per share. Analysts forecast that Amgen will post $12.57 EPS for the current year.

The company also recently declared a quarterly dividend, which was paid on Friday, September 8th. Stockholders of record on Thursday, August 17th were given a dividend of $1.15 per share. The ex-dividend date of this dividend was Tuesday, August 15th. This represents a $4.60 annualized dividend and a dividend yield of 2.44%. Amgen’s dividend payout ratio is currently 41.93%.

COPYRIGHT VIOLATION WARNING: This story was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this story on another domain, it was stolen and republished in violation of US and international trademark and copyright law. The original version of this story can be accessed at https://www.americanbankingnews.com/2017/10/04/amgen-inc-amgn-given-consensus-rating-of-buy-by-brokerages.html.

Several institutional investors and hedge funds have recently added to or reduced their stakes in AMGN. TrimTabs Asset Management LLC boosted its position in shares of Amgen by 88.9% during the first quarter. TrimTabs Asset Management LLC now owns 612 shares of the medical research company’s stock worth $100,000 after buying an additional 288 shares during the period. Alpha Omega Wealth Management LLC boosted its position in shares of Amgen by 19.0% during the first quarter. Alpha Omega Wealth Management LLC now owns 625 shares of the medical research company’s stock worth $103,000 after buying an additional 100 shares during the period. Jackson Grant Investment Advisers Inc. boosted its position in shares of Amgen by 0.6% during the first quarter. Jackson Grant Investment Advisers Inc. now owns 636 shares of the medical research company’s stock worth $104,000 after buying an additional 4 shares during the period. American Beacon Advisors Inc. purchased a new position in shares of Amgen during the first quarter worth $106,000. Finally, Phocas Financial Corp. purchased a new position in shares of Amgen during the second quarter worth $110,000. Institutional investors and hedge funds own 78.10% of the company’s stock.

Amgen Company Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Analyst Recommendations for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.